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Abstract. Pancreatic ductal adenocarcinoma (PDAC) is one of the
most lethal cancers and carries a dismal prognosis. Surgery remains
the best chance of a potential cure for patients who are eligible for
initial resection of PDAC. However, outcomes vary significantly even
among the resected patients of the same stage and received similar treat-
ments. Accurate preoperative prognosis of resectable PDACs for person-
alized treatment is thus highly desired. Nevertheless, there are no au-
tomated methods yet to fully exploit the contrast-enhanced computed
tomography (CE-CT) imaging for PDAC. Tumor attenuation changes
across different CT phases can reflect the tumor internal stromal frac-
tions and vascularization of individual tumors that may impact the clin-
ical outcomes. In this work, we propose a novel deep neural network
for the survival prediction of resectable PDAC patients, named as 3D
Contrast-Enhanced Convolutional Long Short-Term Memory network
(CE-ConvLSTM), which can derive the tumor attenuation signatures or
patterns from CE-CT imaging studies. We present a multi-task CNN to
accomplish both tasks of outcome and margin prediction where the net-
work benefits from learning the tumor resection margin related features
to improve survival prediction. The proposed framework can improve the
prediction performances compared with existing state-of-the-art survival
analysis approaches. The tumor signature built from our model has ev-
idently added values to be combined with the existing clinical staging
system.
Keywords: Pancreatic ductal adenocarcinoma (PDAC), 3D Contrast-Enhanced
Convolutional LSTM (CE-ConvLSTM), Preoperative Survival Prediction
1 Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal of all hu-
man cancers, which has an extremely very poor 5-year survival rate of 9% [15].
Surgical resection, in combination with neoadjuvant chemotherapy, is the only
potentially curative treatment for PDAC patients. Offering surgery to those
who would most likely benefit (e.g., a high chance of long-term survival) is thus
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very important for improving life expectancy. Computed tomography (CT) re-
mains the primary initial imaging modality of choice for the pancreatic cancer
diagnosis. Previous work adopts image texture analysis for the survival pre-
diction of PDACs [1]. However, the representation power of hand-crafted fea-
tures on only venous phase CT might be limited. More recently, deep learning
based approaches have shown good performances not only in traditional med-
ical imaging diagnosis [20,21], but also in prognosis models like outcome pre-
diction of lung cancer [12,25,28] and gliomas [13,11]. The success of 3DCNNs
contributes to capture deep features not only in the 3D gross tumor volume but
also in peritumoral regions. However, such models may not generalize well for
PDAC because some important predictive information is not necessarily existing
in isolated imaging modality/phase. Contrast-enhanced computed tomography
(CE-CT) imaging plays a major role in the depiction, staging, and resectabil-
ity evaluations of PDAC. Typical characteristics of pancreatic cancer include
a hypo-attenuating mass during the pancreatic and venous phases observed in
CE-CT. Enhancement variations among multiple CT phases are known to re-
flect the differences in internal stromal fractions and vascularization of individual
PDACs that impact clinical outcomes [14]. However, the use of multi-phase CE-
CT for quantitative analysis of PDAC prognosis has not been well investigated
in the literature. There is also no established deep learning survival models to
incorporate enhancement variations in multi-phase CE-CT. The margin resec-
tion status, which is known to be associated with the overall survival (OS) of
PDAC patients [10], has been incorporated into the previous radiomics-based
PDAC prognosis model [1]. However, the margin status is only available after
the surgery is conducted. A preoperative prediction of the margin resection is
desired but has not been investigated.
In this paper, we propose a novel 3D Contrast-Enhanced Convolutional Long
Short-Term Memory (CE-ConvLSTM) network to learn the enhancement dy-
namics of tumor attenuation from multi-phase CE-CT images. This model can
capture the tumor’s temporal changes across several phases more effectively
than the early fusion of input images. Furthermore, to allow the tumor resec-
tion margin information to contribute to the survival prediction preoperatively,
we present a multi-task learning framework to conduct the joint prediction of
margin status and outcome. The jointly learning of tumor resectability and tu-
mor attenuation in a multi-task setting can benefit both tasks and derive more
effective/comprehensive prognosis related deep image features. Extensive experi-
mental results verify the effectiveness of our presented framework. The signature
built from the proposed model remains strong in multivariable analysis adjust-
ing for established clinical predictors, and can be combined with the established
criteria for risk stratification and management of PDAC patients.
2 Methods
The preoperative multi-phase CE-CT pancreatic imaging used in this study have
been scanned at three time points for PDACs located at the pancreas head and
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Fig. 1: Example of the multi-phase CE-CT images and PDAC tumor enhance-
ment patterns. Tumor and pancreas masks show the spatial relationship between
the pancreas and tumor. The white arrow depicts a hypo-attenuating tumor; blue
arrow indicates an iso-attenuating mass.
uncinate. After the non-contrast phase, average imaging time delays are 40-
50 seconds for the pancreatic phase and 65-70 seconds for the portal venous
phase. Fig.1 shows three examples to illustrate different tumor attenuation and
resection margins of PDAC patients. Tumor attenuation in specific CT phases
are very important characteristics to identify and detect the tumor. Each row
in Fig.1 represents one PDAC patient, and red boundaries are the tumor an-
notations. The white arrow indicates a typical hypo-attenuating tumor, while
blue arrow shows an iso-attenuating tumor. In previous studies, Kim et al. re-
ported that visually iso-attenuating PDACs are associated with better survival
rates after surgery, as opposed to typical hypo-attenuating PDACs [9]. Hypo-
attenuating mass can be clearly observed in both pancreatic and venous phases
of the first and second patients, indicating low stromal fractions (worse clin-
ical outcomes). For the third patient, even though tumor hypo-attenuating is
observed in pancreatic phase, it then reflects iso- or even hyper-attenuating in
the venous phase compared with its adjacent pancreas regions, indicating high
stromal fractions (better survival). This reminds us that tumor enhancement
changes across phases is a very useful marker to reflect tumor internal variations
and could benefit prognosis. Besides tumor attenuation, another very important
factor is the resection margin indicating the margin of apparently non-tumorous
tissue around a tumor that has been surgically removed. More specifically, the
resection margin is characterized as R0 when no evidence of malignant glands
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was identified microscopically at the primary tumour site. R1 resections have
malignant glands infiltrating at least one of the resection margins on the perma-
nent section and are usually associated with poor overall survival [10]. From the
Fig.1, both tumors from the first and second patient display hypo-attenuating
appearances, but it is clear to see that the second tumor has infiltrated out of
the pancreas shown in tumor and pancreas masks. The pathological evidence
indicates the second patient has the PDAC with R1 resections, and a follow-up
study shows this patient has worse outcome than the first patient. Radiological
observations about tumor attenuation and surgical margins status from CE-CT
imaging motivate us to develop a preoperative PDAC survival model.
We use time points 1, 2, 3 to represent non-contrast, pancreatic, and venous
phases, respectively. A radiologist with 18 years of experience in pancreatic imag-
ing manually delineates the tumors slice by slice on the pancreatic phase. The
segmentation of the pancreas is performed automatically by a nnUNet model
[7] trained on a public pancreatic cancer dataset with annotations [16]. We use
DEEDS [6] to register the non-contrast and venous phases to the pancreatic
phase. Three image feature channels are derived: 1) CT-image of pancreas and
PDAC (background removed) in the soft-tissue window [-100, 200HU] and are
normalized as zero mean and unit variance; 2) binary tumor segmentation mask
and 3) binary pancreas segmentation mask. A multi-phase sequence of image
subvolumes of 64×64×64 pixels3 centered at the tumor 3D centroid are cropped
to cover the entire tumor and its surrounding pancreas regions. The dataset is
prepared for every tumor volume from each phase scan, to build the 4D CE-CT
data for both training and testing (as Xt = {XCTt , XMTt , XMPt }, t ∈ {1, 2, 3},
MT : tumor mask, MP : pancreas mask). Our joint learning network architecture
is shown in Fig. 2. This network has two branches for predicting both the resec-
tion margins and survival outcomes. The branch of resection margins uses one
3D-CNN model with six convolutional layers equipped with Batch Normaliza-
tion and ReLu. Similar 3D architecture has shown good prediction performance
for lung cancer [12]. Input of this branch is the concatenation of CT volumes
at different time points and the corresponding tumor and pancreas masks: e.g.,
X ∈ R5×643 . This branch will try to learn the CT intensity attenuation vari-
ations and the relationships between tumor and surrounding pancreas regions,
which help classify the tumor into different resection status. Note that R0/R1
can only be obtained after the surgery and pathology. Our model can be applied
preoperatively in real scenarios to offer PDAC patients with the appropriate
advice regarding surgical decisions.
The branch of predicting outcomes use CT volumes at each phase (each
phase is CT-MT -MP three-channel input, Xt ∈ R3×643). The aim of this branch
is to capture the tumor attenuation patterns across phases. Tumor attenuation
usually means the contrast differences between the tumor and its surrounding
pancreas regions so that we introduce both the tumor and pancreas masks into
input volumes. The core part of this branch is a recurrence module that allows
the network to retain what it has seen and to update the memory when it sees
a new phase image. A naive approach is to use a vanilla LSTM or ConvLSTM
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Fig. 2: An overview of the proposed multi-task model with CE-ConvLSTM.
network. Conventional ConvLSTM is capable of modeling 2D spatio-temporal
image sequences by explicitly encoding the 2D spatial structures into the tem-
poral domain [2]. A more recent ST-ConvLSTM simultaneously learns both the
spatial consistency among successive image slices and the temporal dynamics
across different time points for the tumor growth prediction [26]. Instead of us-
ing adjacent 2D CT slices and motivated by 3D object reconstruction [4], we
propose to use Contrast-Enhanced 3D Convolutional LSTM (CE-ConvLSTM)
network to capture the temporally enhanced patterns from CE-CT sequences.
CE-ConvLSTM can model 4D spatio-temporal CE-CT sequences by explicitly
encoding their 3D spatial structures into the temporal domain. The main equa-
tions of ConvLSTM are as follows:
ft = σ(W
X
f ∗Xt +WHf ∗Ht−1 + bf ) (1)
it = σ(W
X
i ∗Xt +WHi ∗Ht−1 + bi)
ot = σ(W
X
o ∗Xt +WHo ∗Ht−1 + bo)
Ct = ft  Ct−1 + it  tanh(WXC ∗Xt +WHC ∗Ht−1 + bC)
Ht = ot  tanh(Ct)
where Xt is the CE-CT sequences at time t, ∗ denotes the convolution operation,
and  denotes the Hadamard product. All the gates f, i, o, memory cell C,
hidden state H are 4D tensors. We use a 3 × 3 × 3 convolutional kernel and
128 as the channel dimension of hidden states for the LSTM unit. We employ
3D-ResNet18 [5,3] as the encoder to encode each three-channel input to the
lower-dimensional feature maps for CE-ConvLSTM.
After the concatenation of feature maps from both tasks, the channel num-
ber of this common representation is 256. Then two separate fully-connected
networks will use the common representation for each prediction task. In the
training phase, labels of the resection status and patient overall survival informa-
tion (OS time and censoring status) are known for each input CE-CT sequence.
The weighted binary cross-entropy (BCE) loss is applied to the resection margin
6 J. Yao et al.
prediction task, while the negative log partial likelihood [8,27] is used to predict
the survival outcome yi of this patient which is a continuous score and the loss
function has been used in many deep learning survival models [23,24,22]. This
survival loss is summarized as L(yi) =
∑
i δi(−yi+log
∑
j:tj>=ti
exp(yj)) where
j is from the set whose survival time is equal or larger than ti (tj ≥ ti).
3 Experiments
Dataset. Pancreatic CT scans of 205 patients (with resectable PDACs, mean
tumor size = 2.5 cm) were undertaken preoperatively during non-contrast, pan-
creatic, and portal venous phases (i.e., 615 CT volumes). Only 24 out of 205
patients have R1 resection margins, and the imbalanced class weighting in the
loss is considered. All images were resampled to an isotropic 1 mm3 resolution.
We adopt nested 5-fold cross-validation (with training, validation, and testing
sets in each fold) to evaluate our model and other competing methods. To aug-
ment the training data, we rotate the volumetric tumors in the axial direction
around the tumor center with the step size of 90◦ to get the corresponding 3D CT
image patches and their mirrored patches. We also randomly select the cropped
regions with random shifts for each iteration during the training process. This
data augmentation can improve the network’s ability to locate the desired trans-
lational invariants. The batch sizes of our method and other models are the same
as 8. The maximum iteration is set to be 500 epochs, and the model with the
best performance on the validation set during training is selected for testing.
We first validate the performance from each branch shown in Fig. 2 for single
survival prediction task. Then we incorporate each model with CE-ConvLSTM
and report the results as shown in Table 1. C-index value is adopted as our main
evaluation metric for survival prediction. The C-index quantifies the ranking
quality of rankings and is calculated as follows c = 1n
∑
i∈{1...N |δi=1}
∑
tj>ti
I[yi >
yj ] where n is the number of comparable pairs and I[.] is the indicator function.
ti is the actual time observation of patient i and yi denotes the corresponding
risk. The value of C-index ranges from 0 to 1. The averaged C-index using the
single pancreatic phase is 0.659±0.075 from 3DCNN model. We can see that the
prediction is improved when using early fused CE-CT images (CE-3DCNN, 0.662
vs. 0.659). When CE-ConvLSTM is adopted by incorporating all phases, C-index
is increased by 3% (3DCNN-CE-ConvLSTM) compared with the model only us-
ing the pancreatic phase. 3D-ResNet18 with the pre-trained weights [3] is used
as an advanced model compared to the conventional 3D ConvNets. From Table
1, ResNet3D with CE-ConvLSTM has improved performance versus ResNet3D
with early fusion. Results in this table illustrate that the dynamic enhancement
CT imaging patterns learned/captured by CE-ConvLSTM can help achieve sig-
nificant prediction improvements compared against early fusion CNNs.
To further evaluate the performance of multi-task models, we report the
results in comparison to recent multi-task deep prediction methods [17,12], as
illustrated in Table 2. Tang et al. propose using separate branches of 3D CNNs to
predict both OS time and tumor genotype for glioblastoma (GBM) patients [17].
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Table 1: Validation of CE-ConvLSTM with different CNN backbones.
Model Res-CE-ConvLSTM CE-ResNet3D 3DCNN-CE-ConvLSTM CE-3DCNN
C-index 0.683±0.047 0.675±0.050 0.679±0.052 0.662±0.038
Table 2: Results of different methods. Mul: multi-task; cls: single classification.
Task
Survival Resection Margin: R0/R1
C-index Balanced-ACC Sensitivity Specificity
Proposed Mul 0.705±0.015 0.736±0.141 0.813±0.222 0.659±0.118
Tang et al.[17] Mul 0.683±0.056 0.574±0.090 0.573±0.336 0.575±0.232
Lou et al.[12] Mul 0.649±0.070 0.682±0.091 0.673±0.236 0.690±0.080
CE-ResNet3D cls - 0.604±0.169 0.446±0.347 0.762±0.157
CE-3DCNN cls - 0.583±0.145 0.460±0.312 0.706±0.161
Lou et al. present a multi-task training model on shared hidden representations
from single model [12]. We replace the RMSE loss from the original implemen-
tation of [17] with the negative log partial likelihood loss because it can han-
dle alive patients (whereas authors discarded some patients who are still alive
in [17]). Those models cannot capture tumor temporal enhancement changes.
Classification performances are evaluated by the metrics of Balanced-Accuracy,
Sensitivity, and Specificity. Single classification task uses CE-ResNet3D and CE-
3DCNN can be found in the last two rows in Table 2. We can see the proposed
method that uses CE-ConvLSTM to capture tumor enhancement patterns in-
deed achieves better performance in both tasks than the baseline multi-task
models with early fusion.
In Table 3, univariate and multivariate cox proportional-hazards models are
used to evaluate Hazard Ratio (HR) and log-rank test p-value for each factor in-
cluding deep signature, radiomics signature and other clinicopathologic factors.
To obtain the deep signature on all 205 patients, we use the mean and standard
deviation of risk predictions on the training folds to normalize the risk scores
of the corresponding testing fold. Then we combine results from each testing
fold together. We also build radiomics signature using conventional radiologic
features of input CE-CT images using Pyradiomics [19]. Each phase will pro-
vide 338 features, and thus each patient contains 1014 features in total. Features
are then refined by Lasso-based Cox feature selection [18]. Finally, the selected
features are fed to the Cox regression model to get the signature. Each feature
selection is performed on each training fold, and the number of selected features
varies across different folds. From the statistic analysis (Table 3), the proposed
signature is the strongest prognostic factor in univariate analysis with the high-
est concordance index. The proposed signature remains strong in multivariable
analysis (HR=1.435, p=0.002) adjusting for established clinicopathologic prog-
nostic markers, e.g.: stromal fractions (HR=0.105, p < 0.001), resection margins
(HR=3.704, p < 0.0001), and TNM stage (HR=1.319, p = 0.078). Our pro-
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Table 3: Univariate and Multivariate Cox regression analysis. HR: hazard ratio.
Univariate Analysis Multivariate Cox
Factors HR (95% CI) C-index p-value HR (95% CI) p-value
Stromal Fraction 0.057(0.019-0.17) 0.659 6.38e-7 0.105(0.031-0.0.36) 3.39e-4
Clear fat plane 3.771(2.235-6.364) 0.559 1.39e-5 2.010(1.157-3.490) 0.013
Tumor size 1.693(1.218-2.352) 0.588 0.002 1.568(1.108-2.22) 0.011
Resection margin 4.557(2.772-7.492) 0.577 2.99e-7 3.704(2.147-6.390) 2.51e-6
TNM stage 1.475(1.107-1.966) 0.546 0.008 1.319(0.970-1.790) 0.078
CA19.9 1.001(1.000-1.001) 0.557 0.0207 1.000(0.999-1.001) 0.281
Radiomics signature 1.181(1.109-1.257) 0.645 1.17e-4 1.085(1.004-1.171) 0.038
Signature of [17] 1.704(1.426-2.035) 0.677 4.96e-9 1.035(0.824-1.30) 0.767
Our signature 1.764(1.478-2.105) 0.691 2.81e-10 1.435(1.142-1.803) 0.002
posed one is even stronger than any other CT-derived signature using radiomics
analysis or deep learning model without encoding tumor enhancement patterns.
To demonstrate the added value of the proposed signature to the current
staging system, we plot Kaplan-Meier survival curves in Fig. 3 for patients with
further stratification by our signature after grouping by TNM and Tumor size,
respectively, which are two well-established stratification criteria. The cut-off
for our and radiomics signature is the median score of each signature. We study
two subgroups of patients: 1) patients divided by TNM staging I vs. II-III, 2)
patients divided by the primary PDAC tumor size ≤ 20mm vs. > 20 mm. It
is shown that the proposed signature remains the most significant log-rank test
outcome in the subgroup of patients, while the radiomics signature does not
reach the statistical significance within the patient sub-population of PDAC
tumor ≤ 20mm. Results shown in Fig. 3 demonstrate that after using the current
clinicopathologic TNM staging system or tumor size, our proposed multi-phase
CT imaging based signature can indeed further provide the risk stratification
with significant evidence. This described novel deep signature could be combined
with the established clinicopathological criteria to refine the risk stratification
and guide the individualized treatment of resectable PDAC patients.
4 Conclusion
In this paper, we propose a new multi-task CNN framework for cancer sur-
vival prediction by simultaneously predicting the tumor resection margins for
resectable PDAC patients. The use of CE-ConvLSTM to consider and encode
the dynamic tumor attenuation patterns of PDAC boost the whole framework, to
significantly outperform the early fusion deep learning models and conventional
radiomics-based survival models. Our results also validate that the proposed
signature can serve as both a prognostic and predictive biomarker for subgroup
patients after staging by the well-established pathological TNM or tumor size.
This makes our model very promising in future clinical usage to refine the risk
stratification and guide the surgery treatment of resectable PDAC patients. Fu-
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Fig. 3: Kaplan-Meier analyses of overall survival according to the proposed (1st
row) and radiomics signature (2nd row) in patients with two different strati-
fications (TNM staging and Tumor size). The proposed signature significantly
stratifies all subgroups (TNM I vs II-III; or Tumor size ≤ 20mm vs >20mm).
ture work will consider to integrate with other non-radiological factors (e.g. age,
gender) to achieve better results.
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